Holmusk builds a Real-World Evidence (RWE) platform that aggregates specialty behavioral health data and applies novel analytics to generate evidence-based insights for care providers, payers and patients. Its platform aims to integrate care for people with both behavioral and chronic health needs and to support pharma companies' R&D and commercialization efforts. The company leverages proprietary technology to harness and analyze real-world data and advance data-driven medicine. Holmusk was founded in 2015 and is headquartered in Singapore, with offices in New York City, London and Shanghai. The company intends to use the recent funding to expand its U.S. operations in New York City and to further invest in its analytics technology. Holmusk leverages technology and data science to accelerate research and improve outcomes for people with chronic diseases and behavioral health disorders. The company provides a proprietary modelling platform that informs predictive algorithms and delivers actionable insights for personalized medicine, and it also operates a digital health patient-engagement platform. Holmusk has expanded its behavioral health assets through the acquisition of MindLinc, a behavioral health EHR, giving it one of the largest behavioral health databases in the world. It is developing MindLinc 2.0, combining system dynamics, deep learning neural networks and quantitative systems pharmacology to create predictive disease models based on longitudinal patient data. Holmusk partners with pharma and healthcare providers to apply its analytics and modelling to real-world clinical and research problems. The company is based in Singapore and also maintains offices in the US, UK and Malaysia.

Total raised

$31M

Funding rounds

2

Latest round

Equity

Latest activity

May 2020